Zanubrutinib
Acalabrutinib
(Update) Acalabrutinib in CLL and MCL
Obinutuzumab
JADPRO Roundtable Series: Best Practices in the Use of BTK Inhibitors in CLL
CLL Society
NCCN Guidelines for Patients
Patient Power